STOCK TITAN

Therapeutic Solutions International Inc - TSOI STOCK NEWS

Welcome to our dedicated news page for Therapeutic Solutions International (Ticker: TSOI), a resource for investors and traders seeking the latest updates and insights on Therapeutic Solutions International.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Therapeutic Solutions International's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Therapeutic Solutions International's position in the market.

Rhea-AI Summary
Therapeutic Solutions International (TSOI) has filed for Orphan Drug Designation for its JadiCell Adult Stem Cell Product to treat Acute Respiratory Distress Syndrome (ARDS). The company aims to leverage existing clinical data and Phase III clearance to accelerate the treatment of this fatal lung condition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Therapeutic Solutions International (TSOI) has created CTE Biologics, Inc. as a subsidiary company to commercialize the JadiCell stem cell platform for treating chronic traumatic encephalopathy (CTE). The company has licensed the JadiCell for this indication and is addressing FDA questions before initiating clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.54%
Tags
-
Rhea-AI Summary
Therapeutic Solutions International's spin-off company, Res Nova Bio, successfully delivers cancer-killing virus to breast cancer, causing tumor shrinkage and generating immunity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.09%
Tags
none
Rhea-AI Summary
Clinical stage biotech company Res Nova Bio has partnered with compounding pharmacy Cure Stat Rx to manufacture doses of FloraStilbene™ for a Phase I/II clinical trial in advanced breast cancer patients. The trial aims to assess the drug candidate's immunomodulatory activity. Cure Stat Rx President Ramesh Chigurupati has joined Res Nova's Advisory Board. The collaboration is based on the preclinical and pilot clinical data that supports FloraStilbene as an immune enhancer and natural killer cell activity stimulator in advanced cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
39.13%
Tags
partnership
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.34%
Tags
none
-
Rhea-AI Summary
Therapeutic Solutions International (TSOI) has filed a new Phase III clinical trial application with the FDA for the use of its JadiCell adult stem cells in the treatment of acute respiratory distress syndrome (ARDS). The decision to accelerate development of the ARDS program was influenced by a recent patent victory and positive results from the Phase III clinical trial in COVID-19 associated ARDS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.69%
Tags
clinical trial covid-19
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Therapeutic Solutions International Inc

OTC:TSOI

TSOI Rankings

TSOI Stock Data

2.89M
2.90B
20.03%
Tobacco Manufacturing
Manufacturing
Link
United States
Elk City